Retatrutide: The Triple Agonist Everyone Is Watching

One review of drugs for chronic kidney disease describes retatrutide in seven words: “Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist.” There is no second clause, no hedge and no dose, and it is also, more or less, the whole drug. If you read it slowly enough, it tells you what Eli Lilly built, how it is supposed to work, and why its phase 3 results have made it the molecule that people in obesity drug development keep refreshing their browsers about.

So, plainly: retatrutide is an experimental drug from Eli Lilly that activates three hormone receptors at once, dosed weekly in its trials. In Lilly’s phase 3 TRIUMPH-1 trial, the 12 mg dose produced a mean weight loss of 28.3% at 80 weeks by one method of counting, and all three doses tested met their primary endpoints. Whether and when it gets approved is a separate question, which another article on this site takes up. What follows is a close reading of that seven-word sentence, one word at a time, as if it were a contract someone might later sue over.

What “retatrutide is a” commits Lilly to

Start with the article. “A” agonist, singular. That matters more than it looks. Some of the competition is two drugs in one syringe (CagriSema pairs a GLP-1 drug with an amylin drug), but the sentence promises one molecule doing all three jobs. The sources here don’t give retatrutide’s amino acid sequence, so I won’t pretend to. For scale, its older sibling tirzepatide is, per one cardiovascular review, a “39-amino-acid synthetic peptide” that hits two receptors and earned the nickname “twincretin.”

The nickname for retatrutide would presumably be “tricretin,” except that one of its three targets isn’t an incretin at all. We will get there.

What a receptor agonist is, in plain words

Here is the mechanism with the jargon removed. Your cells have little switches on their surfaces. Hormones float by and flip them. A drug can be built to look enough like the hormone that it flips the switch too, and to hang around for a week instead of a few minutes (the half-life engineering is its own article). Retatrutide is one key cut to fit three different locks.

The official name for a key that turns the lock, rather than just jamming it, is “receptor agonist.” The opposite is an antagonist. That is basically the entire vocabulary.

Two of the three locks are GLP-1 and GIP, the gut hormones that tell the body a meal has arrived (the incretin explainer on this site covers them properly). Tirzepatide already hits both. The third lock is glucagon, and this is where the sentence gets interesting, because glucagon’s best-known job is raising blood sugar. In a drug that is also tested in people with type 2 diabetes, that is sort of like hiring an arsonist for the fire department.

I assume the meeting went something like: “Hey, what if we add the hormone that does the opposite of what we want?” “For energy expenditure.” “Fine, but it needs supervision.”

That is, more or less, the published rationale. A 2026 review of glucagon signaling notes that mazdutide, survodutide and retatrutide are each glucagon-based multi-agonists that “also incorporate GLP-1 receptor-activating moieties to counteract glucagon’s hyperglycaemic effects.” An article headlined “Novo Nordisk’s triple agonist delivers up to 19.7% weight loss” puts it as a trade: “the dual incretin activity of GLP-1 and GIP offsets glucagon’s hyperglycemic effects in triple agonists while retaining energy expenditure benefits.”

So glucagon gets into the molecule, but only chaperoned. It is allowed to do the part where the body burns more energy, and two incretins stand next to it to make sure it does not do the other thing. What exactly the energy part is remains not settled. One line of research proposes that these dual and triple agonists drive “adaptive thermogenesis” (heat production in brown and beige fat) by changing amino acid metabolism there. “Proposed” is the operative word.

“Triple,” and who else is counting to three

The word “triple” is doing marketing work, but it is also accurate, and retatrutide is not alone. That Novo Nordisk article calls retatrutide “the most advanced triple agonist globally,” while reporting on UBT251, another triple GLP-1/GIP/glucagon peptide, which showed weight loss of 13.6% to 19.7% versus 2.0% for placebo in a 24-week phase 2 trial of 205 adults. A 2024 systematic review counted 14 ongoing phase 3 trials of obesity drugs, retatrutide among them. One 2026 review lists dual and triple agonists as one of “the three major axes” of next-generation incretin development, alongside biased agonists and pills.

The obvious next move is a fourth receptor, and then a fifth. To be clear, I am making this up: some company announces a quadruple agonist, a rival answers with a quintuple, and within a decade the leading candidate is a single peptide that binds every receptor in the human body, at which point it is less a drug than a second, more agreeable copy of the patient. It’s fine. Nobody is actually proposing this. The fantasy football logic of drafting every star onto one roster runs into the problem that each extra receptor is another thing that can go wrong.

And things do cost something. A network meta-analysis of 14 trials of glucagon-receptor agonists found retatrutide produced the largest weight reduction versus placebo (a mean difference of 13.44 kg) and the largest HbA1c reduction, but it was also among the agents with “comparatively lower tolerability,” while mazdutide had the most favorable profile. Three locks, more side doors.

On phase 2: the sources here do not lay out retatrutide’s phase 2 trial by itself, so I won’t invent its numbers. The closest thing is a review in Annals of Internal Medicine pooling 26 randomized trials of 15,491 adults without diabetes, which found retatrutide led at 24.2% weight loss on 12 mg weekly, ahead of tirzepatide at 17.8% and injectable semaglutide at 13.9%. Which trials fed that figure isn’t specified in what I have.

What the retatrutide TRIUMPH phase 3 trials have shown

The phase 3 obesity program is called TRIUMPH, which is a confident name to give a trial before it reads out. It worked out.

TRIUMPH-1 (NCT05929066) reported topline results on May 21, 2026. Participants started at an average of 248.5 lb. On the 12 mg dose, the mean loss at 80 weeks was 70.3 lb, or 28.3%, across 2,339 people by what is called the efficacy estimand. That is a bit more than a quarter of a person.

The 9 mg dose produced 25.9%. The 4 mg dose produced 19.0%. On 12 mg, 45.3% of participants lost 30% or more of their body weight, and 65.3% got their BMI below 30. Among people who entered with class 3 obesity (BMI 40 or higher), 37.5% reached a BMI below 30 on 12 mg. In a prespecified blinded extension for people with BMI of at least 35, those on 12 mg reached 30.3% by week 104.

There are two ways of counting in these trials, and they give different answers. By the treatment-regimen estimand, one pipeline tracker puts the TRIUMPH-1 figure at “up to 25%.” Both numbers are real; they answer slightly different questions about who gets counted how. Headlines tend to pick the bigger one. (Headlines are not peer-reviewed.) A separate report mentions phase 3 data of “up to 28.7% weight loss at 68 weeks,” and the sources here don’t reconcile that with the 80-week figures.

TRIUMPH-2 (NCT05929079), in people with obesity and type 2 diabetes, and TRIUMPH-3, in people with severe obesity and established cardiovascular disease, both reported positive toplines on July 23, 2026: up to 20.8% and 22.6% weight loss, respectively. People with diabetes tend to lose less on these drugs, so the lower number there is about what you’d expect. Separately, TRANSCEND-T2D-1, a 40-week diabetes trial of 537 people, showed HbA1c drops of 1.69 to 1.94 points against 0.81 for placebo, and weight loss of 11.5% to 15.3% against 2.6%.

Why the next trial pits Lilly against Lilly

Which brings us to TRIUMPH-5 (NCT06662383), a head-to-head trial of retatrutide against tirzepatide, with primary completion estimated for November 2026. That is this month.

I mean, this is a strange trial to run. Both drugs belong to Lilly. Tirzepatide hit 19.5% and 20.9% at its two top doses in SURMOUNT-1, a different trial with different people, which is exactly why cross-trial comparisons are shaky and why a direct comparison is worth paying for. What is the good outcome here? Retatrutide wins, and Lilly has spent years telling everyone how great its other drug is. Tirzepatide holds up, and the third receptor looks like a lot of chemistry for a little extra. (The site’s comparison piece takes up whether glucagon is worth it.)

Either way, Lilly learns something about Lilly.

So here is the sentence again, with the one clause it was missing: retatrutide is a triple GLP-1/GIP/glucagon receptor agonist, currently being tested against a double one made by the same company. If you are the Lilly sales rep who spent three years explaining why two receptors is the right number, you had better start practicing the word “three.”